G007-LK: Potent Tankyrase 1/2 Inhibitor for Wnt/β-Catenin Pathway Research

Executive Summary: G007-LK is a selective small-molecule tankyrase 1/2 inhibitor with nanomolar potency (IC₅₀: 46 nM for TNKS1, 25 nM for TNKS2), effective in cellular and in vivo models of Wnt/β-catenin pathway-driven cancers (Jia et al., 2017). It inhibits auto-poly(ADP-ribosyl)ation and stabilizes AXIN1/2, facilitating β-catenin degradation [APExBIO]. G007-LK demonstrates antitumor efficacy in APC-mutant colorectal cancer and hepatocellular carcinoma xenografts, reducing tumor growth and β-catenin levels. Its utility spans mechanistic pathway dissection, cell cycle studies, and translational cancer research. Proper handling requires DMSO solubilization and storage at -20°C, with solutions recommended for short-term experimental use.

Biological Rationale

Tankyrases (TNKS1, TNKS2) are poly(ADP-ribosyl) polymerases that regulate protein stability via posttranslational modification. These enzymes modulate the Wnt/β-catenin pathway by promoting AXIN degradation, thereby permitting β-catenin stabilization and nuclear signaling (Jia et al., 2017). Aberrant activation of Wnt/β-catenin signaling is a hallmark in colorectal cancer, especially in tumors bearing APC mutations. Tankyrase activity is also implicated in hepatocellular carcinoma and other malignancies, supporting cell proliferation and survival. Inhibition of tankyrase function leads to AXIN1/2 stabilization, β-catenin degradation, and attenuated transcription of Wnt target genes. G007-LK, developed for high selectivity and potency, enables researchers to dissect this pathway in a controlled, reproducible manner [internal: deeper product applications].

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK selectively binds to the catalytic PARP domain of tankyrase 1 and 2, blocking their enzymatic auto-poly(ADP-ribosyl)ation activity. This inhibition occurs at IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) under standard in vitro assay conditions [APExBIO]. As a result, the degradation of AXIN1/2 is prevented, leading to the assembly of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. This process marks β-catenin for proteasomal degradation, reducing its cytosolic and nuclear levels. In Wnt-activated cellular models such as Wnt3a-induced HEK293 cells, G007-LK suppresses Wnt signaling reporter ST-Luc with an IC₅₀ of 0.05 μM. In APC-mutant SW480 colorectal cancer cells, G007-LK induces dynamic degradasome formation and robust β-catenin depletion [internal: comparative in vitro efficacy].

Evidence & Benchmarks

• G007-LK inhibits auto-poly(ADP-ribosyl)ation of TNKS1/2 with IC₅₀ values of 46 nM and 25 nM, respectively, in recombinant enzyme assays (APExBIO, product page).
• In Wnt3a-induced HEK293 cells, G007-LK suppresses the ST-Luc Wnt reporter with an IC₅₀ of 0.05 μM (APExBIO, product page).
• G007-LK induces formation of AXIN-enriched degradasomes and decreases β-catenin in APC-mutant SW480 colorectal cancer cells (APExBIO, product page).
• In COLO-320DM xenograft mouse models, G007-LK (20–40 mg/kg, oral) reduces tumor growth and β-catenin protein levels, while stabilizing AXIN1/2 (Jia et al., 2017).
• Tankyrase inhibition with G007-LK downregulates YAP/TEAD signaling and upregulates AMOTL1/2 in hepatocellular carcinoma cells, impairing proliferation (Jia et al., 2017).
• G007-LK demonstrates additive/synergistic effects when combined with MEK or AKT inhibitors to suppress cancer cell proliferation (Jia et al., 2017, Table 1).

This article extends prior guides such as G007-LK: Specific Tankyrase Inhibitor for Wnt Signaling Research by providing an updated, citation-dense summary of in vitro, in vivo, and translational benchmarks derived from primary literature and product documentation.

Applications, Limits & Misconceptions

Applications: G007-LK is used for:

• Dissecting Wnt/β-catenin signaling in APC-mutant colorectal cancer and HCC models.
• Studying tankyrase-mediated protein regulation and poly(ADP-ribosyl)ation pathways.
• Investigating β-catenin degradation and AXIN stabilization.
• Evaluating antitumor efficacy in xenograft models (20–40 mg/kg dosing).
• Synergy testing with kinase inhibitors (MEK, AKT).

For a strategic, comparative perspective, see Advancing Cancer Biology: Mechanistic and Strategic Insights, which this article updates with recent peer-reviewed benchmarks and product parameters.

Common Pitfalls or Misconceptions

• Water and ethanol insolubility: G007-LK is only soluble in DMSO (≥26.5 mg/mL); improper solvents can result in precipitation and unreliable dosing (APExBIO).
• No direct effect on unrelated PARPs: G007-LK is selective for tankyrase 1/2 and does not broadly inhibit other PARP family members at recommended concentrations.
• Limited in non-Wnt-driven models: Tumors without Wnt/β-catenin activation or APC mutations may not respond to G007-LK.
• Storage and use: Stock solutions should be stored at -20°C and used promptly to avoid degradation; long-term solution storage not recommended.
• Not a clinical drug: G007-LK is for research use only and is not approved for human therapeutic applications.

Workflow Integration & Parameters

G007-LK (SKU: B5830) is supplied as a solid with molecular weight 529.96 and formula C₂₅H₁₆ClN₇O₃S. Reconstitution should be performed in DMSO to ≥26.5 mg/mL. It is insoluble in water and ethanol. For in vitro studies, serial dilutions are prepared in DMSO and applied to cell culture at final concentrations between 0.01–10 μM, depending on assay sensitivity. In vivo applications utilize oral administration at 20–40 mg/kg in mouse xenograft models. Solutions should be prepared fresh or stored briefly at -20°C. For advanced experimental design, workflows can be adapted from published protocols and in-house guides [internal: mechanistic workflow roadmaps]. APExBIO supplies G007-LK with validated purity and batch-specific documentation. Researchers should monitor for precipitation, avoid repeated freeze-thaw cycles, and confirm Wnt pathway dependency in target systems before use.

Conclusion & Outlook

G007-LK tankyrase 1/2 inhibitor provides a robust, well-characterized tool for dissecting Wnt/β-catenin and Hippo pathway biology in cancer research. Its validated performance in APC-mutant colorectal cancer and hepatocellular carcinoma models has enabled breakthroughs in pathway modulation and drug synergy studies. As a research reagent from APExBIO, G007-LK is positioned for advanced mechanistic studies, translational research, and preclinical target validation. Careful attention to solubility and workflow parameters will maximize reproducibility and scientific insight. For additional product details, refer to the G007-LK tankyrase 1/2 inhibitor product page.